IL22 and inflammatory bowel disease: These data have promoted the paradigm of IL-22 being clinically beneficial to repair epithelial damage in human inflammatory bowel disease (IBD), and has led to a clinical trial (NCT02749630), evaluating the role of recombinant IL-22-Fc (Efmarodocokin alfa) in patients with active IBD.